Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention

International Journal of Radiation Oncology Biology Physics

Volumn 63, Issue 1, 2005, Pages 5-24

  Mehta, Vivek ^a  

^a SWEDISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; DOSIMETRY; ENZYMES; MAGNESIUM COMPOUNDS; ONCOLOGY; PNEUMATICS; TOXICITY; TUMORS;

LUNG CANCERS; PULMONARY FIBROSIS; PULMONARY TOXICITY; RADIATION PNEUMONITIS;

RADIOTHERAPY;

AMIFOSTINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; CAPTOPRIL; CARBON MONOXIDE; CARBOPLATIN; CARVEDILOL; CISPLATIN; CORTICOSTEROID; CYTOKERATIN 19 FRAGMENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; ETOPOSIDE; GEMCITABINE; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; IRINOTECAN; MANGANESE SUPEROXIDE DISMUTASE; MELATONIN; MITOMYCIN C; NAVELBINE; PACLITAXEL; PENTOXIFYLLINE; SURFACTANT PROTEIN D; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1; VINDESINE; BIOLOGICAL MARKER;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROTECTION; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DRUG SAFETY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG NON SMALL CELL CANCER; LUNG VOLUME; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTON RADIATION; RADIATION DOSE; RADIATION PNEUMONIA; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING HABIT; TREATMENT INDICATION; TUMOR LOCALIZATION; BLOOD; FORCED EXPIRATORY VOLUME; LUNG; LUNG TUMOR; METHODOLOGY; PATHOPHYSIOLOGY; PROBABILITY; RADIATION EXPOSURE; RADIATION PROTECTION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; LUNG NEOPLASMS; PROBABILITY; PULMONARY DIFFUSING CAPACITY; RADIATION PNEUMONITIS; RADIATION PROTECTION; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL;

EID: 26944449737     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.03.047     Document Type: Article

References (127)

1. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004; 22:330-353.
2. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15:2996-3018.
3. Roach M 3rd, Gandara DR, Yuo HS, et al. Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors. J Clin Oncol 1995;13:2606-2612.
4. Senzer N. A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: Preliminary findings. Semin Oncol 2002;29:38-41.
5. Leong SS, Tan EH, Fong KW, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 2003;21:1767-1774.
6. Magana E, Crowell RE. Radiation pneumonitis successfully treated with inhaled corticosteroids. South Med J 2003;96:521-524.
7. Inoue A, Kunitoh H, Sekine I, et al. Radiation pneumonitis in lung cancer patients: A retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 2001; 49:649-655.
8. Wang JY, Chen KY, Wang JT, et al. Outcome and prognostic factors for patients with non-small-cell lung cancer and severe radiation pneumonitis. Int J Radiat Oncol Biol Phys 2002;54:735-741.
9. Ohe Y. Treatment-related death from chemotherapy and thoracic radiotherapy for advanced cancer. Panminerva Med 2002;44:205-212.
10. Movsas B, Raffin TA, Epstein AH, et al. Pulmonary radiation injury. Chest 1997;111:1061-1076.
11. Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 2001;13:242-248.
12. Abratt RP, Morgan GW. Lung toxicity following chest irradiation in patients with lung cancer. Lung Cancer 2002;35:103-109.
13. Werner-Wasik M, Yu X, Marks LB, et al. Normal-tissue toxicities of thoracic radiation therapy: Esophagus, lung, and spinal cord as organs at risk. Hematol Oncol Clin North Am 2004;18:131-160, x-xi.
14. Fan M, Marks LB, Lind P, et al. Relating radiation-induced regional lung injury to changes in pulmonary function tests. Int J Radiat Oncol Biol Phys 2001;51:311-317.
15. Rubenstein JH, Richter MP, Moldofsky PJ, et al. Prospective prediction of post-radiation therapy lung function using quantitative lung scans and pulmonary function testing. Int J Radiat Oncol Biol Phys 1988;15:83-87.
16. Choi NC, Kanarek DJ, Grillo HC. Effect of postoperative radiotherapy on changes in pulmonary function in patients with stage II and IIIA lung carcinoma. Int J Radiat Oncol Biol Phys 1990;18:95-99.
17. Choi NC, Kanarek DJ. Toxicity of thoracic radiotherapy on pulmonary function in lung cancer. Lung Cancer 1994;10:S219-S230.
18. Abratt RP, Willcox PA. The effect of irradiation on lung function and perfusion in patients with lung cancer. Int J Radiat Oncol Biol Phys 1995;31:915-919.
19. Robert F, Childs HA, Spencer SA, et al. Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer: Analysis of early and late pulmonary morbidity. Semin Radiat Oncol 1999;9:136-147.
20. Sunyach MP, Falchero L, Pommier P, et al. Prospective evaluation of early lung toxicity following three-dimensional conformal radiation therapy in non-small-cell lung cancer: Preliminary results. Int J Radiat Oncol Biol Phys 2000;48: 459-463.
21. Allen AM, Henning GT, Ten Haken RK, et al. Do dose-volume metrics predict pulmonary function changes in lung irradiation? Int J Radiat Oncol Biol Phys 2003;55:921-929.
22. De Jaeger K, Seppenwoolde Y, Boersma LJ, et al. Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003; 55:1331-1340.
23. Gopal R, Starkschall G, Tucker SL, et al. Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;56:114-120.
24. Miller KL, Zhou SM, Barrier RC, Jr., et al. Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 2003; 56:611-615.
25. Gopal R, Tucker SL, Komaki R, et al. The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys 2003;56:106-113.
26. Brooks BJ Jr., Seifter EJ, Walsh TE, et al. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. J Clin Oncol 1986;4:200-209.
27. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
28. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study. J Clin Oncol 1996;14:1065-1070.
29. Lee JS, Scott C, Komaki R, et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group protocol 91-06. J Clin Oncol 1996;14:1055-1064.
30. Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998;42:469-478.
31. Monson JM, Stark P, Reilly JJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer 1998;82:842-850.
32. Yamada M, Kudoh S, Hirata K, et al. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 1998;34:71-75.
33. Quon H, Shepherd FA, Payne DG, et al. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 1999;43:39-45.
34. Robnett TJ, Machtay M, Vines EF, et al. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2000;48:89-94.
35. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001;51:650-659.
36. Rancati T, Ceresoli GL, Gagliardi G, et al. Factors predicting radiation pneumonitis in lung cancer patients: A retrospective study. Radiother Oncol 2003;67:275-283.
37. Claude L, Perol D, Ginestet C, et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: Clinical and dosimetric factors analysis. Radiother Oncol 2004;71:175-181.
38. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003;21:3201-3206.
39. Johansson S, Bjermer L, Franzen L, et al. Effects of ongoing smoking on the development of radiation-induced pneumonitis in breast cancer and oesophagus cancer patients. Radiother Oncol 1998;49:41-47.
40. van Putten JW, Price A, van der Leest AH, et al. A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 2003;9:2472-2477.
41. Blackstock AW, Lesser GJ, Fletcher-Steede J, et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;51:1281-1289.
42. Onishi H, Kuriyama K, Yamaguchi M, et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: A good local response but no good survival due to radiation pneumonitis. Lung Cancer 2003;40:79-84.
43. Dincbas FO, Atalar B, Koca S. Two-dimensional radiotherapy and docetaxel in treatment of stage III non-small cell lung carcinoma: No good survival due to radiation pneumonitis. Lung Cancer 2004;43:241-242.
44. Seppenwoolde Y, De Jaeger K, Lebesque JV. In regard to Tsujino, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. (IJROBP 2003;55:110-115). Int J Radiat Oncol Biol Phys 2003;56:1208-1209; author reply 1209.
45. Armstrong JG, Zelefsky MJ, Leibel SA, et al. Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer. Ann Oncol 1995;6:693-697.
46. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323-329.
47. Jenkins P, D'Amico K, Benstead K, et al. Radiation pneumonitis following treatment of non-small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy (CHART). Int J Radiat Oncol Biol Phys 2003;56:360-366.
48. Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2003;55:110-115.
49. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 1998;42:1-9.
50. Oetzel D, Schraube P, Hensley F, et al. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 1995;33:455-460.
51. Yorke ED, Jackson A, Rosenzweig KE, et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2002;54:329-339.
52. Lyman JT, Wolbarst AB. Optimization of radiation therapy, III: A method of assessing complication probabilities from dose-volume histograms. Int J Radiat Oncol Biol Phys 1987; 13:103-109.
53. Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method. Int J Radiat Oncol Biol Phys 1989;16:1623-1630.
54. Martel MK, Ten Haken RK, Hazuka MB, et al. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys 1994;28: 575-581.
55. Lee SW, Choi EK, Lee JS, et al. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;56:996-1004.
56. Burman C, Kutcher GJ, Emami B, et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991;21:123-135.
57. Marks LB, Munley MT, Bentel GC, et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 1997;39:563-570.
58. Niemierko A, Goitein M. Modeling of normal tissue response to radiation: The critical volume model. Int J Radiat Oncol Biol Phys 1993;25:135-145.
59. Yorke ED, Kutcher GJ, Jackson A, et al. Probability of radiation-induced complications in normal tissues with parallel architecture under conditions of uniform whole or partial organ irradiation. Radiother Oncol 1993;26:226-237.
60. Seppenwoolde Y, Engelsman M, De Jaeger K, et al. Optimizing radiation treatment plans for lung cancer using lung perfusion information. Radiother Oncol 2002;63:165-177.
61. Seppenwoolde Y, Lebesque JV, de Jaeger K, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys 2003;55:724-735.
62. De Jaeger K, Hoogeman MS, Engelsman M, et al. Incorporating an improved dose-calculation algorithm in conformal radiotherapy of lung cancer: Re-evaluation of dose in normal lung tissue. Radiother Oncol 2003;69:1-10.
63. Kwa SL, Theuws JC, Wagenaar A, et al. Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis. Radiother Oncol 1998;48:61-69.
64. Rodrigues G, Lock M, D'Souza D, et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer - a systematic review. Radiother Oncol 2004; 71:127-138.
65. Willner J, Jost A, Baier K, et al. A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy. Strahlenther Onkol 2003;179:548-556.
66. Hope AJ, El Naqa I, Bradley JD, et al. Radiation pneumonitis/fibrosis risk based on dosimetric, clinical, and location-related factors [Abstract]. Int J Radiat Oncol Biol Phys 2004;60:S204.
67. Rubin P, Johnston CJ, Williams JP, et al. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 1995;33:99-109.
68. Chen Y, Williams J, Ding I, et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 2002;12:26-33.
69. Chen Y, Rubin P, Williams J, et al. Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2001;49:641-648.
70. Ishii Y, Kitamura S. Soluble intercellular adhesion molecule-1 as an early detection marker for radiation pneumonitis. Eur Respir J 1999;13:733-738.
71. Sasaki R, Soejima T, Matsumoto A, et al. Clinical significance of serum pulmonary surfactant proteins A and D for the early detection of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2001;50:301-307.
72. Goto K, Kodama T, Sekine I, et al. Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis. Lung Cancer 2001;34:141-148.
73. Hara R, Itami J, Komiyama T, et al. Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. Chest 2004;125:340-344.
74. Fujita J, Ohtsuki Y, Bandoh S, et al. Elevation of cytokeratin 19 fragment (CYFRA 21-1) in serum of patients with radiation pneumonitis: Possible marker of epithelial cell damage. Respir Med 2004;98:294-300.
75. Koizumi M, Yamazaki H, Toyokawa K, et al. Influence of thoracic radiotherapy on exhaled nitric oxide levels in patients with lung cancer. Jpn J Clin Oncol 2001;31:142-146.
76. Hauer-Jensen M, Kong FM, Fink LM, et al. Circulating thrombomodulin during radiation therapy of lung cancer. Radiat Oncol Investig 1999;7:238-242.
77. Vujaskovic Z, Groen HJ. TGF-beta, radiation-induced pulmonary injury and lung cancer. Int J Radiat Biol 2000;76:511-516.
78. Anscher MS, Kong FM, Andrews K, et al. Plasma transforming growth factor β1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998;41:1029-1035.
79. Barthelemy-Brichant N, Bosquee L, Cataldo D, et al. Increased IL-6 and TGF-β1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2004;58:758-767.
80. 30 and transforming growth factor β. Int J Radiat Oncol Biol Phys 2001;50:899-908.
81. De Jaeger K, Seppenwoolde Y, Kampinga HH, et al. Significance of plasma transforming growth factor-β levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;58:1378-1387.
82. Novakova-Jiresova A, Van Gameren MM, Coppes RP, et al. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 2004;71:183-189.
83. Bentzen SM, Saunders MI, Dische S. From CHART to CHARTWEL in non-small cell lung cancer: Clinical radio-biological modelling of the expected change in outcome. Clin Oncol (R Coll Radiol) 2002;14:372-381.
84. Chen GY, Jiang GL, Qian H, et al. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: A clinical phase II trial. Radiother Oncol 2004;71:157-162.
85. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial. CHART Steering Committee. Lancet 1997;350:161-165.
86. Kirkbride P, Hatton M, Lorigan P, et al. Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) 2002;14:361-366.
87. Oral EN, Bavbek S, Kizir A, et al. Preliminary analysis of a phase II study of paclitaxel and CHART in locally advanced non-small cell lung cancer. Lung Cancer 1999;25:191-198.
88. Saunders MI, Rojas A, Lyn BE, et al. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) 2002;14:352-360.
89. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a phase I/II trial. Int J Radiol Oncol Biol Phys 2002;54:348-356.
90. Narayan S, Henning GT, Ten Haken RK, et al. Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer. Lung Cancer 2004;44:79-88.
91. Wu KL, Jiang GL, Liao Y, et al. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: A phase I/II dose escalation clinical trial. Int J Radiat Oncol Biol Phys 2003;57:1336-1344.
92. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial. J Clin Oncol 2001;19:127-136.
93. Bhatnagar A, Flickinger JC, Bahri S, et al. Update on results of multifield conformal radiation therapy of non-small-cell lung cancer using multileaf collimated beams. Clin Lung Cancer 2002;3:259-264.
94. Koenig TR, Munden RF, Erasmus JJ, et al. Radiation injury of the lung after three-dimensional conformal radiation therapy. AJR Am J Roentgenol 2002;178:1383-1388.
95. Wurstbauer K, Deutschmann H, Sedlmayer F, et al. Non-small-cell lung cancer: Dose escalation by target splitting with asymmetric collimation. Clin Lung Cancer 2001;3:151-153.
96. Dirkx ML, Essers M, van Sornsen de Koste JR, et al. Beam intensity modulation for penumbra enhancement in the treatment of lung cancer. Int J Radiat Oncol Biol Phys 1999;44:449-454.
97. Dirkx ML, Heijmen BJ. Beam intensity modulation for penumbra enhancement and field length reduction in lung cancer treatments: A dosimetric study. Radiother Oncol 2000;56:181-188.
98. van Sornsen de Koste J, Voet P, Dirkx M, et al. An evaluation of two techniques for beam intensity modulation in patients irradiated for stage III non-small cell lung cancer. Lung Cancer 2001;32:145-153.
99. Murshed H, Liu HH, Liao Z, et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;58:1258-1267.
100. Mackie TR, Balog J, Ruchala K, et al. Tomotherapy. Semin Radiat Oncol 1999;9:108-117.
101. Scrimger RA, Tome WA, Olivera GH, et al. Reduction in radiation dose to lung and other normal tissues using helical tomotherapy to treat lung cancer, in comparison to conventional field arrangements. Am J Clin Oncol 2003; 26:70-78.
102. Sun LM, Leung SW, Wang CJ, et al. Concomitant boost radiation therapy for inoperable non-small-cell lung cancer: Preliminary report of a prospective randomized study. Int J Radiat Oncol Biol Phys 2000;47:413-418.
103. Pottgen C, Eberhardt W, Bildat S, et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): A pilot phase I/II trial. Ann Oncol 2002;13:403-411.
104. Hof H, Herfarth KK, Munter M, et al. Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2003;56:335-341.
105. Lee SW, Choi EK, Park HJ, et al. Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung. Lung Cancer 2003; 40:309-315.
106. Suit H. The Gray Lecture 2001: Coming technical advances in radiation oncology. Int J Radiat Oncol Biol Phys 2002; 53:798-809.
107. Bonnet RB, Bush D, Cheek GA, et al. Effects of proton and combined proton/photon beam radiation on pulmonary function in patients with resectable but medically inoperable non-small cell lung cancer. Chest 2001;120:1803-1810.
108. Satoh H, Okumura T, Yamashita YT, et al. Proton irradiation for non-small cell lung cancer. Arch Intern Med 1998;158:1379-1380.
109. Shioyama Y, Tokuuye K, Okumura T, et al. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;56:7-13.
110. Miyamoto T, Yamamoto N, Nishimura H, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2003;66:127-140.
111. Kadono K, Homma T, Kamahara K, et al. Effect of heavy-ion radiotherapy on pulmonary function in stage I non-small cell lung cancer patients. Chest 2002;122: 1925-1932.
112. Jeremic B, Shibamoto Y, Milicic B, et al. Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone. Lung Cancer 2003;40:317-323.
113. Rosenzweig KE, Mychalczak B, Fuks Z, et al. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. Cancer J 2000;6:82-87.
114. Yorke ED, Wang L, Rosenzweig KE, et al. Evaluation of deep inspiration breath-hold lung treatment plans with Monte Carlo dose calculation. Int J Radiat Oncol Biol Phys 2002; 53:1058-1070.
115. Rosenzweig KE, Hanley J, Mah D, et al. The deep inspiration breath-hold technique in the treatment of inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000;48:81-87.
116. Kwok E, Chan CK. Corticosteroids and azathioprine do not prevent radiation-induced lung injury. Can Respir J 1998;5:211-214.
117. Antonadou D, Coliarakis N, Synodinou M, et al. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 2001;51:915-922.
118. Antonadou D, Throuvalas N, Petridis A, et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;57:402-408.
119. Komaki R, Lee JS, Milas L, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: Report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 2004;58:1369-1377.
120. Werner-Wasik M, Scott C, Movsas B, et al. Amifostine as mucosal protectant in patients with locally advanced non-small cell lung cancer (NSCLC) receiving intensive chemotherapy and thoracic radiotherapy (RT): Results of the Radiation Therapy Oncology Group (RTOG) 98-01 study. Int J Radiat Oncol Biol Phys 2003;57:S216.
121. Ward WF, Lin PJ, Wong PS, et al. Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor captopril evaluated by high-resolution computed tomography. Radiat Res 1993;135:81-87.
122. Wang LW, Fu XL, Clough R, et al. Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis? Radiat Res 2000;153:405-410.
123. Molteni A, Moulder JE, Cohen EF, et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 2000;76:523-532.
124. Ozturk B, Egehan I, Atavci S, et al. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: A double-blind randomized trial. Int J Radiat Oncol Biol Phys 2004;58:213-219.
125. Vijayalaxmi, Reiter RJ, Tan DX, et al. Melatonin as a radio-protective agent: A review. Int J Radiat Oncol Biol Phys 2004;59:639-653.
126. Jonsson OE, Bjermer L, Denekamp J, et al. Perivascular cell protection in vivo and increased cell survival in vitro by the antihypertensive agent carvedilol following radiation. Eur J Cancer 1999;35:1268-1273.
127. Guo H, Epperly MW, Bernarding M, et al. Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) intratracheal gene therapy reduction of irradiation-induced inflammatory cytokines does not protect orthotopic Lewis lung carcinomas. In Vivo 2003;17:13-21.